Aardvark Therapeutics (AARD) Change in Acquisitions & Divestments (2025 - 2026)

Aardvark Therapeutics (AARD) reported Change in Acquisitions & Divestments of $34.2 million for Q1 2026, up 184.78% on a YoY basis from $12.0 million in Q1 2025, and up 17.09% sequentially from $29.2 million in Q4 2025.

Aardvark Therapeutics (AARD) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends

Aardvark Therapeutics (AARD) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $34.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 184.78% year-over-year to $34.2 million; the trailing twelve-month figure through Mar 2026 stood at $102.2 million (up 750.17% YoY), and the FY2025 full-year result was $80.0 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments advanced to $34.2 million in Q1 2026, from $29.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $34.2 million in Q1 2026 to a low of $9.5 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,140.12 Bn 66,139.83 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.73 Bn -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn -
4 BeOne Medicines 472.60 Bn 467.81 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.34 Bn 115.09 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.14 Bn 61.39 Bn 3.31 Bn
7 Belite Bio 62.79 Bn 62.79 Bn -
8 Argenx Se 56.19 Bn 51.00 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.50 Bn 34.49 Bn 959.66 Mn
10 Aardvark Therapeutics 142.89 Mn 22.93 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 34.25 Mn
Mar 31, 2026 34.25 Mn
Dec 31, 2025 29.25 Mn
Dec 31, 2025 29.25 Mn
Sep 30, 2025 29.25 Mn
Sep 30, 2025 29.25 Mn
Jun 30, 2025 9.50 Mn
Jun 30, 2025 9.50 Mn
Mar 31, 2025 12.03 Mn
Mar 31, 2025 12.03 Mn